Women 18 years or older, who have recurrent ovarian cancer will be enrolled in this study.
After consenting to participate in this trial, they will undergo screening process which will
involve medical exam and blood work. If found eligible to participate in the trial, they will
be given olaparib to be taken on all 28 days of the cycle and investigational AZD 6738 from
days 1-7. For the first cycle, the subject will need to come in every week for lab tests and
physical exam - this will help the treating physician determine an adverse event as soon as
it happens. After that, patients are expected to come in every month at the end of each cycle
(each cycle is 28 days).
Patients will undergo scans for tumor assessments every 2 cycles and if stable disease or
response to therapy is documented after cycle 4, imaging will continue every 3 cycles
1. Patients ≥ 18 years of age and post-menopausal.
2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and a life
expectancy of at least 6 months.
3. Patients must have high grade serous ovarian, primary peritoneal, and/or fallopian
tube cancer histologically or cytologically confirmed at the University of
Pennsylvania or JHH that is recurrent and for which standard curative measures do not
exist or are no longer effective.
4. All patients must have at least one lesion deemed safe to biopsy and be willing to
undergo mandatory biopsies. Cohorts A & B: 75% will require all biopsies (Pre-Tumor,
On-Treatment, PD). If safe, 25% will require a biopsy only at PD. Cohort C: 100% will
require all biopsies (Pre-Tumor, On-Treatment, PD).
5. All patients must have a measurable disease by RECIST v1.1.
6. Germline BRCA mutation status:
Cohorts A and B: Patients with unknown BRCA status or negative BRCA germline mutation
status will be permitted to enroll in the study. Patients with known BRCA germline
mutations will be permitted to enroll up to a maximum of 10 patients per cohort.
Cohort C: All patients must have either a germline or somatic BRCA mutation or other HRD
germline mutation, or tumor is HRD positive.
9. Adequate renal function, defined as measured creatinine clearance ≥ 51 ml/min.
10. Adequate hepatic function, defined as AST and ALT levels ≤ 2.5 X ULN (for subjects with
liver metastases, AST or ALT ≤ 5 × ULN) and total bilirubin < 1.5 X ULN, absent Gilbert's
11. Adequate bone marrow function, defined as absolute neutrophil count (ANC) ≥ 1.5 X
109/L), platelet count ≥ 100 x 109/L , and hemoglobin ≥ 10 g/dL (in the absence of
transfusion within 28 days prior to dosing).
12. Patients must be at least 2 weeks from previous therapy (chemotherapy, hormonal
therapy, and radiation therapy, or investigational agents; 6 weeks for mitomycin C) to
initiate screening and 3 weeks from previous therapy to initiate treatment.
13. Platinum sensitive (recurrence >6 months by RECIST 1.1 imaging from last platinum)
patients may not have had more than 3 prior therapies. Platinum resistant (recurrence <
6months by RECIST 1.1 imaging from last platinum regimen) patients may not have had more
than 3 prior therapies since the development of platinum resistance.
14. Prior treatment with a PARPi is not permitted for Cohorts A and B. Patients enrolled in
Cohort C have acquired resistance to PARPi monotherapy, i.e. initial response to a Parp
inhibitor followed by disease progression while on a PARP inhibitor. Patients may have not
received chemotherapy in the interval between PARPi monotherapy and enrollment. Cohort C
patients must also be platinum sensitive.
15. Patients who have had major surgery must be fully recovered and ≥4 weeks post-operative
prior to enrolling on study.
16. Patients must be able to swallow oral medications (capsules and tablets) without
chewing, breaking, crushing, opening or otherwise altering the product formulation. They
should not have gastrointestinal illnesses that would preclude the absorption of AZD6738 or
olaparib, which are oral agents.
17. Post menopausal 18. Able to understand and voluntarily sign consent 19. Patients with a
history of brain metastases diagnosed greater than 1 year prior to study entry may be
considered if they received sterilizing therapy to the CNS (resection or radiation) and
have been CNS recurrence-free for the 1-year period.
1. Patients with known brain metastases diagnosed within 1 year will be excluded from
this clinical trial because of their poor prognosis and because they often develop
progressive neurologic dysfunction that would confound the evaluation of neurologic
and other adverse events.
2. Patients who have had prior AZD6738 or other cell cycle checkpoint inhibitors such as
other ATM or ATR inhibitor, WEE-1 inhibitor or CHK1 (or 1/2) inhibitors.
3. Patients with a serious cardiac condition, such as congestive heart failure; New York
Heart Association Class III/IV heart disease; unstable angina pectoris; myocardial
infarction within the last 3 months; valvulopathy that is severe, moderate, or deemed
clinically significant; or arrhythmias that are symptomatic or require treatment.
Resting ECG with QTc > 470 msec on 2 or more time points within a 24 hour period or
family history of long QT syndrome.
4. Patients with a systolic blood pressure <90 mm Hg, or recurrent symptomatic
5. Lack of recovery of prior adverse events due to prior cancer therapy to Grade ≤1 (NCI
CTCAE v4.03; except alopecia). Stable persistent grade 2 peripheral neuropathy may be
allowed as determined on a case-by-case basis at the discretion of the PI. Patients
with platinum-related hypomagnesemia (on replacement) will be eligible.
6. Uncontrolled intercurrent illness including, but not limited to, symptomatic
congestive heart failure, unstable angina pectoris, cardiac arrhythmia, clinically
significant GI bleeding or hemoptysis within 28 days prior to the start of the study,
or psychiatric illness/social situations that would limit compliance with study
7. Another previous, active or current invasive malignancy within the last 5 years, with
the exception of curatively treated stage Ia cervical carcinoma, or resected stage IA,
grade 1 endometrial cancer, noninvasive non-melanoma skin cancers, DCIS of the breast
or other solid tumors including lymphomas (without bone marrow involvement) curatively
treated with no evidence of disease > 5 yrs . Patients with localized triple negative
breast cancer may be eligible who are disease free at least three years out from
8. Immunocompromised patients or HIV-positive patients on HAART due to potential drug
9. Concomitant use of known strong CYP3A inhibitors (eg. itraconazole, telithromycin,
clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir,
saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (eg.
ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout
period prior to starting olaparib is 2 weeks.
10. Concomitant use of known strong (eg. phenobarbital, enzalutamide, phenytoin,
rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort ) or
moderate CYP3A inducers (eg. bosentan, efavirenz, modafinil). The required washout
period prior to starting olaparib is 5 weeks for enzalutamide or phenobarbital and 3
weeks for other agents.
11. Patients with myelodysplastic syndrome, Acute myeloid leukemia or with features
suggestive of MDS/AML.
12. Major surgery within 4 weeks of starting study treatment and patients must have
recovered from any effects of any major surgery.
13. Patients with a known hypersensitivity to AZD6738 or olaparib or any of the excipients
of the product.
14. Platinum refractory (progress in first line platinum therapy) are excluded
15. Patients receiving any systemic chemotherapy or radiotherapy (except for palliative
reasons) within 3 weeks prior to study treatment
16. Patients with known active hepatitis (ie Hepatitis B or C) due to risk of transmitting
the infection through blood and other body fluids
17. Previous allogneic bone marrow transplant or double umbilical cord blood
18. Whole blood transfusions in the last 120 days prior to entry to the study